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Abstract
Background: Recruitment and retention of participants are critical to the success of a randomised controlled trial.
Gaining the views of potential trial participants who decline to enter a trial and of trial participants who stop the
trial treatment is important and can help to improve study processes. Limited research on these issues has been
conducted on healthy individuals recruited for prevention trials in the community.
Methods: Semi-structured interviews with people who were eligible but had declined to participate in the Aspirin
for Asymptomatic Atherosclerosis (AAA) trial (N = 11), and AAA trial participants who had stopped taking the trial
medication (N = 11). A focus group with further participants who had stopped taking the trial medication (N = 6).
(Total participants N = 28).
Results: Explanations for declining to participate could be divided into two groups: the first group were
characterised by a lack of necessity to participate and a tendency to prioritise other largely mundane problems.
The second group’s concern was with a high level of perceived risk from participating.
Explanations for stopping trial medication fell into four categories: side effects attributed to the trial medication;
starting on aspirin or medication contraindicating to aspirin; experiencing an outcome event, and changing one’s
mind.
Conclusions: These results indicate that when planning trials (especially in preventive medicine) particular
attention should be given to designing appropriate recruitment materials and processes that fully inform potential
recruits of the risks and benefits of participation.
Trial registration: ISRCTN66587262.
Background
Recruitment and retention of participants are critical to
the success of a randomised controlled trial (RCT). The
CONSORT requirement for RCTs to include a flow dia-
gram of participant passage through the trial has
improved the accessibility and scrutiny of accrual and
drop-out rates [1,2]. However, reasons for non-participa-
tion are not always recorded, investigated or published.
Gaining the views of participants (and potential partici-
pants) themselves is important for a number of reasons.
A growing literature has identified problems with parti-
cipants making sense of the RCT procedure and the
rationale behind randomisation [3-6]; reluctance to
accept the principle of equipoise [6]; and preferences for
certain treatment arms [5-7]. Indeed when given the
choice between being randomly allocated to treatment
and receiving one’s treatment of choice (in a patient
preference trial) randomisation has been found to be
unpopular [8]. Investigating trial candidates’ views of the
recruitment process can help to improve study processes
(such as content and delivery of participant information)
and recruitment rates [9].
Few studies have accessed in depth the views of indivi-
duals who have declined to participate in a trial, though
the available evidence suggests that declining is often
the result of candidates being unwilling, because of
treatment preference, to accept the uncertainty, rando-
misation and risks associated with an RCT [3,5,7,10].
However, research has mainly focused on patients taking
part in trials with overt differences between treatment
arms; there is limited research on healthy individuals
taking part in research [11,12]; and a particular gap
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blind placebo controlled trials. Further, the views of trial
participants who drop out before the trial completion
date have been relatively neglected.
The Aspirin for Asymptomatic Atherosclerosis trial
(hereafter referred to as the AAA trial), was a double-
blind placebo-controlled randomised trial assessing the
effectiveness of low dose aspirin (100 mg/daily) in pre-
venting cardiovascular events in otherwise healthy indi-
viduals with asymptomatic atherosclerosis identified by
a low ankle brachial index [13]. The index is an effective
and simple method of identifying peripheral athero-
sclerosis [14]; an index of <0.95 is associated with an
increased risk of cardiovascular events and mortality
[15]. In this paper, we report a qualitative study of peo-
ple’s explanations for declining to participate in the trial
(thus affecting accrual rates) or, having begun the trial,
stopping the trial medication (thus affecting drop-out
rates).
Methods
A detailed description of the AAA trial procedure has
been published [13]. 165,795 individuals identified
through general practice records as aged between 50
and 75 years old (on 1
st January 1998) were invited to
attend for screening with the ankle brachial index. Elig-
ibility criteria for attending included not currently taking
aspirin or warfarin and no history of coronary heart dis-
ease, stroke or peripheral arterial disease. Of the 29,147
individuals who attended screening, 4914 had an ankle
brachial index ≤0.95 (the high risk cut off) in at least
one leg, of whom 641 did not meet additional eligibility
criteria and 923 declined, leaving 3350 people who were
randomised to receive either aspirin (100 mg daily) or
placebo for a mean duration of 8.2 (1.6) years [13]. This
represents an accrual rate of approximately 8 out of 10
eligible candidates. Non-adherence with study medica-
tion throughout the trial was 40% (person-years of fol-
low-up) [13]; 15% of participants took their medication
for less than 6 months.
Qualitative study
Ethical approval was granted by Greater Glasgow (Com-
munity/Primary Care), Lanarkshire, and Lothian Local
Research Ethics Committees. Individual interviews (N =
22) were conducted with individuals who had attended
the screening, were eligible to enter the trial but had
declined to participate in the trial (N = 11), and with
participants who started the trial but stopped taking the
medication (N = 11). A focus group (N = 6) was also
conducted with additional trial participants who had
stopped the trial medication but who were still receiving
annual follow up by the trial team.
Recruitment
Purposive sampling was undertaken in order to reach
individuals with particular relationships to the AAA
trial, i.e. people who had declined to participate and
trial participants who had stopped the medication, but
also to ensure inclusion of people with a range of differ-
ent lengths of time taking the medication; sampling con-
tinued until theoretical saturation was achieved [16].
All eligible individuals who declined to participate in
the trial during a 3 month period were sent a partici-
pant information leaflet for the qualitative study and
opt-in reply slip by post. All those expressing an interest
in the qualitative study were telephoned by HCE to dis-
cuss participation (including the options to participate
in an individual interview or a focus group) and, where
willing, to arrange an interview. The accrual rate in this
group was approximately 1 out of 10 individuals who
were sent an invitation. (NB It was not feasible to
arrange a focus group for individuals in the ‘declined
trial’ group due to their widespread locations).
All participants who had stopped trial medication and
were scheduled to have an annual phone follow-up
within a 1 month period were informed about the quali-
tative study by the research nurse during the follow-up
phone call. As above, all those expressing an interest
were telephoned by HCE to check willingness and
arrange an interview or focus group. The accrual rate in
this group was approximately 1 out of 5 individuals
approached.
HCE, a non-clinical social researcher, conducted the
semi-structured interviews and focus group using a
topic guide based on three main topic areas: the screen-
ing, preventive medicine and aspirin, and trial participa-
tion. This paper focuses on data generated about the
latter area [see appendix for topic guide]. With written
consent all interviews and focus groups were audio
recorded, transcribed verbatim and anonymised. The
data extracts presented in the results section are labelled
with the participant’s age, gender and group; a number
replaces name and location to preserve anonymity.
Analysis was informed by grounded theory and the
constant comparative method [17,18]: Transcripts were
read and re-read, emerging themes were noted and pre-
liminary (open) codes were formed (by HCE), which
further developed throughout the fieldwork. Codes were
discussed with SCB and FGRF, and refined into a coding
framework, which HCE used to systematically code all
transcripts. QSR NVivo 2.0 was used to facilitate storage
and coding of data.
Results
Interview and focus group participants were between 55
and 77 years old (mean = 65.2, standard deviation = 6.9).
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city, and there was a wide range in socioeconomic back-
ground: the median Carstairs deprivation index was 3.
This index is based on postal code classification from
1991 census, with a range from I (most affluent) to VII
(most deprived) [19,20]. The current sample included
individuals from all seven levels.
Declining to participate
The explanations given for declining trial participation
could be divided into two distinct groups relating to
perceived necessity and perceived risk. For one group
(N = 6), respondents’ explanations indicated a lack of
necessity to participate in the trial, and were charac-
terised by mentions of largely mundane problems (either
trial-specific or more circumstantial) that nonetheless
took priority.
Trial-specific explanations included concerns about
the trial involving too much commitment or too long a
duration, particularly for individuals at the upper end of
the age range.
“I think it was too much of a hassle for me [...] and I
thought well if it’sn o tt o os e r i o u s ,w h i c hm i g h t
sound stupid, I’m not gonna bother... At the end of
the day would it have been beneficial?” (P3.5, male,
58, declined trial)
“The thought of this going on for five years, seemed
to me a long time, I didn’tw a n tt oc o m m i tm y s e l f . ”
(P3.6, female, 73, declined trial)
A procedural aspect of the trial was the focus of con-
cern for two respondents - the blood tests conducted at
the baseline appointment to measure serum cholesterol
levels, which led to fear and discomfort in these two,
and thus to their declining to participate.
“Well the nurse said I was a fraction over and I
could go on the trial. I said I didn’tm i n dt h a tb u t
they was gonna take some blood from me. And I
says, ‘no way!’ That was it. Because I’m terrified of
needles” (P3.11, female, 73, declined trial)
Circumstantial explanations emphasised issues such as
unfortunate timing due to unrelated health problems at
the time of recruitment:
“I was happy to take part in it, but unfortunately I
was in [the hospital] having problems and that’s why
Id i d n ’t take part, and I was going to see a specialist
and there was a possibility it was either a- well they
thought- a hernia, or an ulcer, so I spoke to my own
doctor and he said obviously not to take part in this
until we’d sorted the other problem out.” (P3.2,
female, 62, declined trial)
A few reported not seeing any personal benefits or
incentives to participate in the trial, with one mention-
ing lack of financial incentive.
These largely mundane reasons had overridden any
initial desire to take part in the trial. The priority of
these reasons, and the lack of perceived necessity to par-
ticipate (for example, “it’sn o tt o os e r i o u s ”, P3.5),
demonstrated the lack of risk perceived from the ankle
brachial index result for these respondents.
In contrast, the second group (N = 5) were charac-
terised by a high level of risk perceived from participating
in the trial. For three respondents this translated into an
unwillingness to accept the blinding and random alloca-
tion in the trial, and most importantly the possibility of
being allocated to the placebo. One respondent disliked
t h ei d e ao fb e i n ga‘guinea pig’ and acted on this by
requesting aspirin on prescription from his own general
practitioner, while one respondent chose the less formal
route of self-medicating with over-the-counter aspirin.
“I tried to analyse what you were offering under the
aspirin trial and when I found out you knew I was at
risk, but you were prepared to put me on a dummy
pill I said, get lost! And [...] they can’t tell you what
you were on. So I walked out of the trial at that
stage and I went to my own doctor... I spoke to him
and told him what was happening, and he said, ‘Do
you want to go on aspirin?’ and I said, ‘Well it
sounds like I might have to. I’d sooner be on it
rather than nothing.’ So I have the 75 mg aspirin.”
(P3.8, male, 68, declined trial)
“I buy [aspirin] in Superdrug, and I just take one you
know dissolved in water most days, maybe five times
a week” (P3.10, female, 61, declined trial)
For two respondents the risk they perceived from
aspirin led to their declining. Despite being keen to par-
ticipate, one man had previously experienced adverse
reactions to aspirin, and thus stated that he would have
participated if he could have been guaranteed to receive
the placebo.
“they had said in the letter it was aspirin...I thought
well I’ll go and see er...I get tummy trouble, so I try
to avoid aspirin if I can [...] and I didn’t really fancy
going on a prolonged sort of dose of it. So that was
the main reason I didn’t go on the trial. [...] I said,
‘well I don’t really want aspirin’, [thinking that] they
might just give me the placebo, but to some extent
the trial’s not really working properly if I go in and
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dummy’” (P3.1, male, 59, declined trial)
A second respondent who declined in order to avoid
aspirin reported a long history of adverse reactions to
various medications and now sought to avoid all con-
ventional medication. For her this avoidance included
the placebo:
“I thought, no I’ll try and take care of myself other
ways [...] I take supplements, I’m also vegetarian any-
way, so I thought I would increase my fruit and veg,
I take oils, I read a lot of health supplements, I also
attend an Ayuverdic doctor. [...] I didn’tk n o ww h a t
was in the dummy pill! The placebo, I didn’tk n o w
what was in that, so I wasn’t willing to swallow it
[either].” (P3.9, female, 60, declined trial)
In comparison to the first group, the risk perceived by
this second group was associated with a perceived
necessity to engage in action of some sort - seeking
aspirin or identifying other lifestyle behaviours with the
aim of minimising the risk associated with their ankle
brachial index result.
Stopping trial medication
For the respondents who had started to participate in
the trial but had stopped the medication, their explana-
tions for stopping fit into four main categories: Side
effects attributed to the trial medication; starting a
course of aspirin or medication contraindicated to
aspirin; experiencing an outcome event [13]; and ‘chan-
ged mind’.
Seven respondents described side effects they had
experienced and had attributed to the trial medication.
They reported consulting the trial team or their own
doctor, and being advised to stop the trial medication,
either temporarily or permanently. Side effects ranged
from knee swelling to tongue tingling, but the most
typical were gastro-intestinal as discussed by focus
group participants:
FG2.4: again I found that I had stomach problems
w i t ht h et a b l e ts oIa s s u m e dt h a ti tm u s tb et h e
aspirin (yeah) I was taking it and I kept saying, ‘I
can’t be ill, I don’t even know what it is.’ I stopped it
a n ds t a r t e di to nt w oo c c a s i o n sa n dd i df i n dt h a tI
was waking up at night with a slight gnawing feeling
in the stomach and
FG2.2: I was exactly the same
FG2.4: Did you have the same? Well that’s good to
know yeah
(FG2.4: female, 63; FG2.2: female, 61)
No respondent expressed anger in relation to these
side effects (even when probed in the interview) or
reported regret for participating despite the effects being
severe in some cases:
“I really felt I’d got gall bladder trouble again
because [the pain] was from here right through into
me kidneys and really severe. So I went to my GP,
and she just checked round and said straight away,
‘Don’t take anymore, and ring [the trial] and tell
them’ [...]
HCE: so once you got it sorted out, how did you feel
about the trial then?
I felt like well I’v el e tt h e md o w n ,b u ta ts a m et i m e
your health does come first and if that tablet aspirin
were gonna kill me...!
HCE: did you feel angry for getting the symptoms
that you got?
No, no, because you go into it and you do know
what you’re doing I mean that were it, it were just
one of them things, there’ss o m ep e o p l ea sy o u
know who’ve started with it and they’ve still no pro-
blem.” (P2.3, female, 55, stopped medication)
Indeed this respondent’s comment about letting the
trial down and disappointment in having to cease full
participation in the trial was shared by others (for exam-
ple most of the focus group participants). Furthermore,
one respondent’s disappointment about having stopped
led him to contact the trial with the aim of restarting
after a side effect-free period.
Six respondents had been prescribed aspirin, or a
medication contraindicated to aspirin, for a range of
conditions. Again there was an indication of disappoint-
ment in some of these respondents, but rather than an
emotional reaction it was typical for the respondent to
simply describe what happened in a somewhat resigned
manner, accepting the requirements of the changes to
their health. For example:
“I took angina, and I went and I [came] off the trial
Husband: and you’d then to start taking aspirin, you
didn’t know whether you were on aspirin or the pla-
cebo under the trial
Aye, and so that’s why I come off it, but we’re now
taking an aspirin a day.” (P2.11, female, 76, stopped
medication)
“It was the fatal type of malaria I had...I was all
wired up the whole time I was in [hospital] and they
discovered I had heart fibrillation... After that I’dt o
go on warfarin you see, so that’s why I had to drop
out because warfarin and aspirin just don’ta g r e e ”
(P2.5, female, 77, stopped medication)
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tion eleven months into the trial, which was one of the
AAA trial outcome events. S i m i l a r l yt ot h o s ew h oh a d
experienced side effects he did not blame the trial,
rather he seemed to be fatalistic about the event.
HE: So how did you feel about that, about going into
the trial?
“I was glad in the sense that they found something
that maybe, you know. You don’t know if you’re tak-
ing the real aspirin or the dummy aspirin, I felt in a
sense that it was helping, you know, till I actually
took the heart attack”
(Later in interview):
HE: Did it change how you felt about the trial after
having the heart attack?
“In what sense, do you mean whether the trial con-
tributed? I thought maybe the trial to me in a way
highlighted it, [that] my heart was bad you know...
No I didn’t blame anything on the trial, no, I felt
that after all if it was gonna do it, then it was gonna
happen you know...” (P2.8, male, 63, stopped
medication)
In contrast to the medical explanations presented so
far, the final category of explanation can be classified as
‘changed mind’. Examples of this included two respon-
dents who initially reported stopping the medication
due to forgetfulness, but later in their interviews
revealed an underlying dislike of medication, as demon-
strated in the two quotes from the following respondent
at different points in his interview:
“The only reason I stopped was simply because I
kept forgetting to take the tablets you know [...] I’m
getting terrible forgetful. And I mean it would just
b eas o r t[ o f ]s h a mf o rm et os a yI ’ve been taking it
when I haven’t, you know. I think trials are- they are
good things you know...”
(Later in interview):
“If you’re taking a lot, it knocks the hell out of your
stomach. [...] Given the choice, I’dr a t h e rn o tt a k e
medication full stop.” (P2.6 male, 55, stopped
medication)
Two respondents explained the lack of necessity they
attributed to taking medication associated with the lack
of risk they perceived from the ankle brachial index
(echoing one group of explanations for declining).
“I think if it had been medication that I needed to
take, I would have taken it. And that sounds as
though I wasn’t committed, but I was when I started
certainly, but you know I’dg ot ot a k et h e ma n d
‘goodness me, I haven’t taken them this week’.” (P2.4
male, 72, stopped medication)
These two respondents described managing without
medication all their life and thus seeing no reason for
starting now.
In this sample, respondents who stopped the medica-
tion due to changing their mind seemed to do so early
on, whereas most of those who stopped for medical rea-
sons had taken the trial medication for a longer period -
up to 3 years in some cases - by the time that they
stopped.
Discussion
The current findings add further insight to the growing
literature about trial participation by identifying key rea-
sons for declining to participate, and for stopping medi-
cation, in a double-blind placebo-controlled preventive
medicine trial. First the accounts of eligible individuals
who declined to participate in the trial suggest two dis-
tinct groups of explanation: for one group there was a
lack of perceived necessity to engage in any action
(including participating in the trial) which was associated
with a lack of perceived risk from the ankle brachial
index, and the explanations focused instead on largely
mundane issues. In the second group the central concern
was the risk perceived from participating in the trial. The
accounts of trial participants who had stopped their trial
medication revealed four main categories of explanation
- the first three related to medical events (experiencing
side effects attributed to the medication, starting a course
of medication that would interfere with the trial, and
experiencing an outcome event), and a final category
which can be summarised as ‘changing one’s mind’.
The explanations for declining that focused on the
risks perceived from the trial - including being blinded,
randomised and thus no guaranteed receipt of aspirin -
echo a treatment preference found by previous studies
[3,5,7]. Our findings revealed both preferences for
receiving, and for avoiding the treatment. In previous
studies respondents’ preferences have been associated
with the benefits and drawbacks of an ‘experimental’
treatment [3,5]. In contrast, our respondents’ prefer-
ences were associated with personal and public knowl-
edge about aspirin due to its familiarity and widespread
use [16] and demonstrated respondents’ lack of clinical
equipoise. What the respondents overlooked, however,
was that the effectiveness of aspirin as a primary pro-
phylactic was still unknown and the purpose of conduct-
ing the AAA trial. Indeed the recently published AAA
trial results demonstrate that these respondents’ strong
preference for aspirin was not supported [13].
The findings demonstrate the importance of ‘mun-
dane’ explanations for declining which were not
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ment allocation, but which focused on procedural
aspects of the trial or unrelated health circumstances at
the time of invitation. For these respondents participat-
ing in the trial was not perceived as sufficiently attrac-
tive or necessary to override these factors. Indeed these
accounts revealed a lack of perceived necessity for any
action to address the increased risk (including partici-
pating in the trial), which highlights the lack of risk that
these respondents perceived from their ankle brachial
index result and/or atherosclerosis.
While there is a clear distinction for trialists between
individuals who decline to participate and trial partici-
pants who stop their trial medication, the current data
demonstrate some overlap in the explanations given by
the two groups: those who stopped the medication
because they ‘changed their mind’,a n dt h o s ew h o
declined to participate for ‘mundane’ reasons shared the
same lack of necessity for action and a lack of perceived
risk from the ankle brachial index.
That medical reasons (both related and unrelated to
the trial) result in some participants stopping the trial
medication is inevitable in a trial of long duration with
individuals of older age and/or increased risk. Outcome
events are to be expected, as analysing the proportion of
participants in each arm who experience an outcome
event is after all the main purpose of a trial. Further-
more establishing the number and type of side effects
experienced is another crucial element of the trial’sa n a -
lysis. Of interest, however, was the disappointment
expressed by respondents who had experienced an out-
come event or side effect and to some extent by those
whose medical circumstances had required a prescrip-
tion of aspirin or other medication thus preventing
them continuing to take the trial medication. Such dis-
content was not directed at the trial for possibly having
caused the side effect or not having prevented the out-
come event, rather it emerged as regret at having to end
their full participation in the trial accompanied by a
feeling that they had let the trial down. This is in line
with previous findings that a commonly reported driver
for participating in research is the desire to help others
[4,7,11], and that the participatory experience can lead
to the feeling of a ‘warm glow’ [21]. Many of these
respondents appeared to accept this change in circum-
stances (and thus the requirement to stop the trial med-
ication) in a somewhat fatalistic and resigned manner,
and pointed out that when the risks to their health out-
weighed the benefits of participating, it is understand-
ably their health that takes priority.
Strengths and limitations
The current paper extends our knowledge about trial
participation by exploring the perspectives of those
invited to participate in a previously unexplored context
- a double-blind placebo-controlled randomised trial in
preventive medicine with a community population. The
findings will be relevant to other clinical trials in parti-
cular preventive medicine and community based trials.
S o m eo ft h ef i n d i n g sa r el i k e l yt ob es p e c i f i ct ot h eu s e
of aspirin - for example the strong treatment prefer-
ences expressed by some respondents which were asso-
ciated with their own personal knowledge and also
public awareness about aspirin [16] - although these
findings will be useful to trials with other ‘common-
place’ medicines.
Sampling in this study was subject to the usual
response bias of interview studies with an opt-in recruit-
ment process. The sample of participants who had
stopped the trial medication was limited to those who
w e r eh a p p yt ob ef o l l o w e du pb yt h et r i a lt e a m .H o w -
ever the resulting sample comprises two groups of indi-
viduals that can be difficult to access; in particular the
accounts of participants who have stopped trial medica-
tion are under researched.
Implications
The findings will be of interest to those running trials
(particularly in a community population and/or preven-
tive medicine) to address factors that may be affecting
recruitment and adherence, while ensuring that conduct
remains ethical. Asking individuals for consent to be
contacted again at a later date could prove an effective
strategy for those who are keen to participate in the
trial but decline due to health problems not related to
the trial or other life circumstances. This may be useful
in trials with long recruitment periods. For individuals
who have concerns about particular procedural aspects
of a trial, procedures could be put in place to encourage
potential recruits to engage in discussion with a research
nurse allowing them to express their concerns and
explore possible solutions, and even making minor pro-
tocol adjustments in special cases.
T h ef i n d i n gt h a tas u b s t a n t i a lg r o u po fo u rr e s p o n -
dents did not regard participation (or indeed any action)
as necessary demonstrated the little risk perceived by
these respondents from their ankle brachial index result.
This highlights the importance of ensuring that potential
recruits understand the meaning of the results of any
clinical measures used whichm a k et h e me l i g i b l ef o ra
trial.
With individuals who see no necessity to participate,
the potential benefits to others and to medical research
that may result from the trial could be emphasised [22]
though equal time should be spent discussing all options
and ensuring that coercion is avoided [9].
For potential recruits with strong treatment prefer-
ences it would be unethical to attempt to persuade
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Furthermore when the treatment is widely available as
an over-the-counter medication, like aspirin, such indivi-
duals will seek the medication by themselves as demon-
strated by a couple of our respondents. However, where
feasible a patient preference trial design would enable
inclusion of such participants.
T h ei n e v i t a b l eo c c u r r e n c eo fs i d ee f f e c t sa n dh e a l t h
events in a trial population such as the AAA population
highlights the importance of ensuring that potential
recruits are provided with understandable written infor-
mation about likely side effects and procedures to follow
in the event of experiencing them, and contact details of
trial staff that can help with any query (as was the case
in the AAA trial). Informing potential recruits about all
the possible side effects may lead to slower recruitment
by putting some individuals off, but the resulting sample
may be one that adheres for a longer duration. Recruit-
ment of trial participants is expensive so any efforts that
can result in a longer lasting sample are worth investing
time and effort into.
Conclusions
The reasons for declining to participate in randomised
controlled trials and the reasons for trial participants
stopping their trial treatment are of key importance to
clinical researchers who are concerned with optimising
both recruitment and adherence, while ensuring conduct
remains ethical and non-coercive. With regards to the
AAA trial we have outlined two distinct categories of
reasons for declining: strong treatment preference (high
perceived risk from the trial and/or the ABI result) and
lack of perceived necessity (low perceived risk from the
ABI result). The level of risk that a respondent per-
ceived (from their ABI result and its meaning, from ran-
domisation, from taking aspirin, or from not taking
aspirin) and the level of perceived necessity to engage in
action of some sort (including participating in the trial)
were the key drivers. The categories of reasons for stop-
ping medication fit into two distinct groups: changing
one’s mind (associated with a low perceived risk from
the ABI result and lack of perceived necessity - echoing
one of the declining categories), and medical reasons
(which are inevitable in a trial involving people of older
age and/or increased risk).
Adjustments to trials could address these issues of
declining and stopping; where feasible patient-preference
arms may be useful for addressing strong treatment pre-
ferences, minor protocol adjustments could be made for
individuals with concerns about procedural aspects,
more time could be spent with potential recruits ensur-
ing comprehension of eligibility criteria (in this case the
meaning of a low ABI) and discussing the risks and ben-
efits of the trial, and for individuals who decline due to
temporary circumstances (such as unrelated health
i s s u e s ) ,c o n s e n tc o u l db es o u g h tt oc o n t a c tt h e ma ta
later date.
These findings indicate that in planning future trials
(especially in preventive medicine) particular attention is
given to designing appropriate recruitment materials
and processes that fully inform potential recruits of the
risks and benefits of participation, and incorporate time
for discussion of the issues that our respondents raised.
Appendix
Relevant Section of Topic guide
Individuals who declined to participate
￿ Reasons for declining to participate in the trial
￿ Perceptions of why people choose to participate
￿ Views on not knowing the trial tablet’s identity
Participants who stopped medication
￿ Experience of taking part in the ‘aspirin trial’
￿ Reasons for participating in the trial
￿ Feelings about taking the trial tablet for 5 years
￿ Feelings about not knowing the tablet’s identity
￿ Reasons for stopping the trial medication and sub-
sequent reflections
All respondents
￿ Advantages and disadvantage of taking part in the
trial
￿ Prior trial experience
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